編者按：最近，隨著中國(guó)內(nèi)陸宮頸癌疫苗獲批上市，引發(fā)了公眾越來(lái)越多的關(guān)注。宮頸癌疫苗即人類乳頭瘤病毒（HPV）疫苗，HPV屬于脫氧核糖核酸（DNA）病毒，除了可以引起子宮頸上皮癌，還涉及其他類型上皮癌。HPV對(duì)于乳腺癌發(fā)生的作用，近年來(lái)一直由于各個(gè)研究報(bào)告相互矛盾而存在爭(zhēng)議。

　　2018年6月8日，歐洲乳腺癌?？茖W(xué)會(huì)《乳腺》在線發(fā)表意大利米蘭大學(xué)歐洲腫瘤研究所、希臘雅典大學(xué)醫(yī)學(xué)院安德烈亞斯塞格羅斯醫(yī)院、圣薩瓦綜合腫瘤醫(yī)院的研究報(bào)告，通過(guò)現(xiàn)代DNA微陣列（DNA芯片）技術(shù)，確定了乳腺癌患者乳腺和宮頸的HPV感染發(fā)生率。

　　該前瞻研究入組乳腺癌患者201例，詳細(xì)記錄病史，并在手術(shù)期間無(wú)菌條件下，從腫瘤、健康鄰近乳腺組織、陽(yáng)性前哨淋巴結(jié)、宮頸采集標(biāo)本，通過(guò)DNA微陣列技術(shù)，對(duì)所有標(biāo)本分析了24種HPV的DNA。

　　結(jié)果發(fā)現(xiàn)，雖然所用技術(shù)靈敏度高，但是任何乳腺或淋巴結(jié)標(biāo)本均未發(fā)現(xiàn)HPV。宮頸標(biāo)本發(fā)現(xiàn)HPV陽(yáng)性28例，根據(jù)分析表明，HPV陽(yáng)性與陰性患者相比：

• 孕激素受體陽(yáng)性乳腺癌顯著較多（P=0.041）

• 兩個(gè)或三個(gè)淋巴結(jié)陽(yáng)性顯著較多（P=0.002）

　　因此，根據(jù)該研究細(xì)致的標(biāo)本采集，結(jié)合非常敏感的微陣列技術(shù)，表明HPV與乳腺癌無(wú)關(guān)。不過(guò)，宮頸標(biāo)本HPV陽(yáng)性患者的某些乳腺癌特征存在顯著差異。

Breast. 2018 Jun 8;40:165-169. [Epub ahead of print]

HPV infection and breast cancer. Results of a microarray approach.

Andriana Kouloura, Electra Nicolaidou, Ioannis Misitzis, Euaggelia Panotopoulou, Vasilios Smyrniotis, Giovanni Corso, Paolo Veroneci, Nikolaos Arkadopoulos.

European Institute of Oncology, Milan, Italy; National and Kapodistrian University of Athens School of Medicine, Andreas Syggros Hospital, Athens, Greece; Saint Savvas General Anticancer Hospital, Athens, Greece.

OBJECTIVES: Human papilloma virus (HPV) has been implicated in several types of epithelial cancer. The role of HPV in breast carcinogenesis has been a matter of debate fueled by conflicting reports in recent years. The aim of this study is to identify the prevalence of breast and cervical HPV infection in cancer patients by using a modern microarray approach.

MATERIALS AND METHODS: In the present prospective study, 201 breast cancer patients were included. For each patient a detailed medical history was taken and during the operation, under sterile conditions, samples were collected, from the tumour, the healthy adjacent breast tissue and any positive sentinel lymph nodes. In addition, for each patient a cervical sample was also collected. All samples were analysed for DNA of 24 types of HPV using a microarray technique.

RESULTS: Despite the high sensitivity of the technique used, no HPV DNA was identified in any of the breast or lymph node samples. Our analysis showed that patients with HPV positive cervical samples (28 cases) were more likely to have tumors with positive progesterone receptors (p=0.041) and were also more likely to have two or three positive lymph nodes (p=0.002).

CONCLUSION: In the present study, a combination of careful sample collection and a very sensitive microarray approach showed no correlation between HPV and breast cancer. However some characteristics of the breast tumors were different among patients with HPV DNA in their cervical samples.

DOI: 10.1016/j.breast.2018.05.010